Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 mutant||Advanced Solid Tumor||sensitive||Pemigatinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).||detail...|
|PubMed Id||Reference Title||Details|
|Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828||Full reference...|